Pharmaceuticals
/C O R R E C T I O N -- DoctorOnCall/
In the news release, NCSM & DoctorOnCall Join Forces to Promote Free COVID-19 Vaccination and Booster Doses (Including On-site and House-to-House), issued 12-Feb-2023 by DoctorOnCall over PR Newswire, we are advised by the company that the 7th paragraph, 1st sentence, should read "For more informa...
2023-02-17 08:00
5606
Dalton Announces Major Expansion in Commercial Sterile Manufacturing Capacity
TORONTO, Feb. 17, 2023 /PRNewswire/ -- Dalton Pharma Services today announced a major strategic expansion of its sterile filling and pharmaceutical manufacturing capacity. The capital expansion plan includes a new state-of-the-art, fully automated cGMP sterile filling line with the flexibility t...
2023-02-17 01:37
5398
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies,announced the ...
2023-02-16 20:36
7665
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...
2023-02-16 17:10
4285
Aqilion announces pre-clinical licensing and strategic research collaboration agreement with Merck
HELSINGBORG, Sweden, Feb. 16, 2023 /PRNewswire/ -- AQILION AB ("Aqilion") today announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. Me...
2023-02-16 15:00
2313
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committ...
2023-02-16 14:00
3986
Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial
YANTAI, China, Feb. 16, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA2101, an investigational anti-IL-4Rα antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innovative biological prod...
2023-02-16 08:15
5081
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology ...
2023-02-16 08:00
4969
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/ -- Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovativ...
2023-02-15 21:30
4579
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved in the U.S. - * HLX02 (trastuzumab for injection, trade name in China: HANQUYOU; trade name inEurope: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®) has been approved in more than 3...
2023-02-15 16:49
4445
GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS
- Study recommends a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus (HCV) infection with DAA Therapies - Review of implementation science projects toward HCV Elimination by 2030 in Asia proved effective in improving patient outcomes - Efficacy ...
2023-02-15 10:00
3369
Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy
ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-02-15 08:00
5421
Groundbreaking clinical trial underway to improve vision in individuals with advanced Retinitis Pigmentosa (RP)
Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Au...
2023-02-15 05:10
2804
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced inFebrua...
2023-02-15 04:51
3083
Eurofins Discovery Collaborating with Invasight on Cancer Therapies
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry, today announced its collaboration withInvasight, a Switzerland-based biotech developing cancer therapies. The collaboration focuses on advancing first-in-cla...
2023-02-15 00:10
2924
CJ Biomaterials Teams with Banila Co. to Develop New 100% Biobased Cosmetic Jar using Amorphous PHA
WOBURN, Mass., Feb. 14, 2023 /PRNewswire/ -- CJ Biomaterials, Inc., a division ofSouth Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoates (PHAs), has produced the first cosmetic jar based on their amorphous PHA technology, under the tradename, PHACT™. The cosmetic jar was...
2023-02-14 22:00
3782
U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine
* Modified agreement also includes the development of an updated vaccine in fall 2023 GAITHERSBURG, Md., Feb. 13, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, toda...
2023-02-13 21:00
5014
Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610
TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has recently completed the first batch of subject enrollment for its novel adjuvanted recombinant shingles vaccine, ...
2023-02-13 15:02
5345
Nippon Express Obtains GDP Certification of Compliance with WHO Standards at 2 Domestic Locations: West Japan Pharmaceutical Center and Kyushu Pharmaceutical Center
- Storage and Transport Offered in Two Temperature Ranges, Following East Japan Pharmaceutical Center - TOKYO, Feb. 10, 2023 /PRNewswire/ -- Nippon Express Co., Ltd. (hereinafter "Nippon Express"), a group company of NIPPON EXPRESS HOLDINGS, INC., has acquired Good Distribution Practice (GDP) ce...
2023-02-10 14:00
4202
AcuraBio expands cGMP plasmid DNA CDMO services with Cytiva's latest single-use purification technology to alleviate supply constraints for mRNA and cell & gene therapies
* AcuraBio selects Cytiva's latest two-step purification protocol to offer a productive plasmid DNA service to its customers globally to alleviate supply constraints for mRNA and cell & gene therapies * The latest purification technology will offer efficient processing time for plasmid DNA pr...
2023-02-10 09:34
7421
Week's Top Stories
Most Reposted
Futurise Impact Report 2025 Highlights Progress in Regulatory Innovation Future-Ready Technologies
[Picked up by 272 media titles]
2026-09-09 13:26
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
AKSADRON Releases Impact Report 2025, Showcasing the Growth of Malaysia's Drone Sports Talent Ecosystem
[Picked up by 255 media titles]
2026-09-14 15:36
Qunabox Group Opens '99 Quna Festival,' Debuting Consumer-Facing Physical AI Entertainment
[Picked up by 251 media titles]
2026-09-09 11:01Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
10077
